Sweden Achieves 18-Year Ahead of Schedule Smoke-Free Target

Dec.08.2022
Sweden Achieves 18-Year Ahead of Schedule Smoke-Free Target
Sweden achieves smoking rate of 5.6%, becoming the only European country to reach EU's no smoking goal ahead of schedule.

Swedish authorities have officially confirmed that the smoking rate in Sweden has now decreased to 5.6%. This makes Sweden the only European country to be on track to achieving the EU's goal of becoming smoke-free, achieving this target 18 years ahead of the 2040 deadline.


At an event organized by the Stockholm Snus Nicotine Committee, participants evaluated Sweden's incredible achievements and leadership in the fight against smoking. The country is on track to become the world's first to be defined as "smoke-free" and have a smoking population of less than 5%.


Since the 1980s, Sweden has achieved a remarkable feat unmatched by any other country in the world, reducing its smoking rate from 35% to less than 6%. The country now boasts the second lowest smoking rate in Europe, which is only half that of the next lowest country. In contrast, the average smoking rate in the EU is around 23%, which is four times higher than Sweden's. Notably, Europe also has the lowest tobacco-related death rate in the world.


On November 30, 2022, a group of leading public health experts, consumer advocates, and harm reduction professionals celebrated this achievement in Stockholm and once again called on policymakers around the world to ensure the availability of less harmful smoking alternatives as aids for quitting smoking.


Delon Human, President and Stockholm event organizer of Health Diplomats, stated during the event that if all 1.1 billion smokers worldwide were to switch to a less harmful nicotine replacement product, it could prevent disease and save millions of lives globally. Sweden has found a solution for smokers and we must work together to follow their example and save lives around the world.


This incredible success story sheds light on Sweden's secret to success, where the key factor is an open-minded attitude towards less harmful alternatives to smoking. While snus has long been at the forefront of harm reduction efforts, in recent years, nicotine pouches and e-cigarettes have become another valuable tool for Swedish smokers looking to quit.


Sweden's gradual harm reduction approach differs significantly from the measures proposed by the International Tobacco Control Organization. Advocates for harm reduction in the EU have been pushing for reductions in harm to be included in cancer prevention plans. Despite the fact that the Tobacco Control Framework Convention recognizes harm reduction as a viable option, the World Health Organization continues to refuse to acknowledge its benefits.


Professor Karl Fagerström stated during the event, "Sweden's upcoming presidency of the European Union is a great opportunity to share the country's successful stories, which accounts for 5% of the EU, with other member countries. We hope that Sweden will generously share this knowledge with other nations.


Speakers at the conference emphasized the need for evidence-based and comprehensive tobacco control policies. Therefore, it is imperative to implement the concept of reducing tobacco harm on a broader level to support smoking cessation.


Ensuring that the smoking alternatives with lower health risks are inexpensive, accessible, and easy to use, is a crucial prerequisite for Sweden's success in replicating it in other countries.


The Nicotine Oral Committee is a global nonprofit organization dedicated to assisting governments, health officials, and the public in building knowledge about nicotine oral products, challenging unfounded biases and stereotypes. The organization deals with political, scientific, consumer matters, and related product innovations. Their views are independent of any brand/manufacturer and are tailored to the individual and population health needs of adult smokers.


2FIRSTS will continue to follow and report on this topic. Updates will be available on the 2FIRSTS app. Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
Former BAT global content lead Andy Parton has left the company and launched Destreza, a London-based AI-native marketing consultancy. Parton previously worked across BAT's New Category brands Vuse, Velo and glo and had also served as Global Brand Lead for Vuse Go. Destreza says it will advise consumer businesses on AI in brand strategy, operating models, capability and agency configuration, using specialist AI agents to support research, strategy and creative development. BAT reported £3.621 billion in New Category revenue in 2025.
Sep.22
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
Ahead of the 2026 NACS Show, 2Firsts interviewed Chris Rapanick, NACS managing director of research, on changes reshaping the U.S. convenience-store tobacco and nicotine market. NACS data show cigarette sales declining while smokeless alternatives, including nicotine pouches, continue to grow. The interview also examines higher OTP margins, shifting backbar space, weaker store traffic, regulatory uncertainty and NACS’ outlook for 2027, offering a retailer-side view of one of the world’s largest nicotine markets.
Interview
Oct.03
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24